INTRODUCTION AND OBJECTIVES: ontinuous activation of hypoxia-inducible factor (HIF) is important for renal cell carcinoma (RCC) progression as well as resistance acquisition against mTOR and VEGFR inhibitors. Recently a HIF2a antagonist (PT2385) has been developed, and is currently being investigated in a phase I clinical trial for advanced or metastatic clear cell RCC (ccRCC) patients who had prior tyrosine kinase inhibitors. However, resistant mechanisms against the HIF2a antagonist seems to be a next problem in the near future. The aim of this study was to find activated signals involved in the HIF2a antagonist-resistance after acquiring sunitinib resistance.
METHODS: First, we established sunitinib resistant 786-o (SU-R-786-o) cells in vivo by oral gavage treatment. Instead of the HIF2a antagonist administration, we completely knocked out the HIF2a gene expression in SU-R-786-o cells by using a recent genome editing technology, CRISPR/Cas9 system, with two different single guide RNAs against HIF2a. We identified their characteristics in cell proliferation assay and western blot. These cells were also analyzed in proteomics and RNA sequence analyses to elucidate their activated signals.
RESULTS: By using CRISPR/Cas9 system, we succeeded in establishing HIF2a knockout sunitinib resistant 786-o (HIF2a-KO-SU-R-786-o) cells. Cell morphology was changed from spindle to round shape in HIF2a-KO-SU-R-786-o cells. In addition, cell proliferation in HIF2a-KO-SU-R-786-o cells became significantly slower than in the parental cells as well as SU-R-786-o cells (P < 0.01). After recovering cell proliferation in HIF2a-KO-SU-R-786-o cells, proteomics and RNA sequence revealed that CXCR4 expression was dramatically up-regulated in SU-R-786-o cells compared to the parental cells, however, it was decreased in HIF2a-KO-SU-R-786-o cells compared to SU-R-786-o cells. Another surprise was that serine biosynthesis pathway was accelerated in HIF2a-KO-SU-R-786-o cells compared to SU-R-786-o cells.
CONCLUSIONS: Based on the proteomics and RNA sequence analyses, we found that CXCR4 upregulation or serine biosynthesis might be critical for acquiring resistance against multi kinase inhibitors or HIF2a antagonist. Even though both drugs target angiogenesis pathway, the activated signals were altered in the different therapeutic stage by the different drugs administration. The inhibitions of serine biosynthesis pathways might be potential targeted therapy for advanced or metastatic ccRCC which shows resistance to HIF2a agonist after acquiring resistance to multi kinase inhibitors. 
INTRODUCTION AND OBJECTIVES:
Next generation preclinical models of renal cell carcinoma (RCC) now offer the ability to predetermine de novo drug resistance in fresh patient tumor samples prior to targeted therapy. Implantation of tumor specimens into the chorioallantoic membrane (CAM) of the chicken embryo results in high engraftment efficiencies within two days, permitting large scale 00 tumor avatar 00 studies. Functional tumor heterogeneity studies, which can be performed in context of drug resistance within two weeks, can guide the selection of drugs and predict drug resistance outcomes for RCC patients. This ultrafast PDX model is mirrored by high-frequency ultrasound imaging that permits quantification of tumor volume and tumor vascularity in a high-throughput manner.
METHODS: Several core biopsies were extracted from primary tumors and metastases from clear cell RCC, chromophobe RCC, and type 1/2 papillary RCC patients and submitted to xenografting into the CAM of chick embryos. At least 6 regions of the primary tumor were xenografted and 3 metastases were xenografted. At least N>36 per region was submitted to xenografting with half of these treated with sunitinib or vehicle (DMSO). At T¼10 days post-implantation, high frequency ultrasound imaging was used to quantitate tumor vascularity, tumor volume, tumor blood flow and and tumor blood volume. After imaging, total exome sequencing was performed to identify any genetic mutations for correlation to drug resistance.
RESULTS: Using this 00 tumor avatar 00 model paired with a prospective RCC patient cohort, we observe intratumoral functional heterogeneity in the context of sunitinib treatment, as determined by highfrequency ultrasound imaging, highlighting its potential interventional role in the clinic. Exome sequencing and gene copy number variation analysis did not reveal DNA mutation signatures that were associated with resistance to sunitinib treatment within this intratumoral set of PDX biopsies.
CONCLUSIONS: These findings suggest that genetic tumor heterogeneity exists, but evidence for a direct relationship to the drug resistant phenotype was not manifest in DNA mutations. Therefore, these results support a phenotype based readout to predict drug resistance within 10 days as opposed to a genotype signature, and that drug resistance to targeted therapy is heterogeneous across the primary tumor.
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